CTOs on the Move

Alliqua

www.alliqua.com

 
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner`s ability to deal with the challenges of healing both chronic and acute wounds. Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company`s Mist Therapy System® uses painless, noncontact low-frequency ultrasound to ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.alliqua.com
  • 2150 Cabot Blvd West
    Langhorne, PA USA 19047
  • Phone: 215.702.8550

Executives

Name Title Contact Details

Similar Companies

Induchem Usa

Induchem Usa is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Pain Therapeutics

Pain Therapeutics, Inc. is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Designs

Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...